Guangdong Journal of Animal and Veterinary Science ›› 2025, Vol. 50 ›› Issue (2): 110-116.DOI: 10.19978/j.cnki.xmsy.2025.02.17
Previous Articles Next Articles
SHI Guanwen,OU Zhaojia ,LONG Haibin,RAO Gan,HE Jiaxin,HU Minhua*
Online:
Published:
石观稳,欧兆佳,何嘉欣,龙海斌,饶干,胡敏华*
通讯作者:
基金资助:
Abstract: In order to improve the management of dog pruritus and improve the quality of life and animal welfare, 18 dogs with“severe pruritus”grade were selected by visual analogue scale(PVAS). Olatinib maleate,IL ⁃ 31 monoclonal antibody, peramine, dexamethasone and prednisolone were used respectively. The onset speed, antipruritic effect and adverse reactions of the drugs were compared. The results showed that olatinib had the most rapid and significant antipruritic effect after 4 hours of treatment,and IL ⁃ 31 monoclonal antibody had the most significant antipruritic effect after 8,24,48 and 72 hours of treatment. Dexamethasone and prednisolone caused a significant increase in white blood cells and neutrophils in the affected dogs,and the other treatments were normal. In conclusion,olatinib maleate and IL ⁃ 31 monoclonal antibody have obvious advantages in the speed of onset, antipruritic effect and safety.
Key words: Canidae, Pruritus, Comparison of antipruritic effect
摘要: 为更好地做好犬只瘙痒管理,提高犬只生活质量和动物福利,该试验采用视觉模拟 评分法(PVAS)筛选“严重瘙痒”等级的患犬18例,分别使用马来酸奥拉替尼、IL-31单克隆抗 体、扑尔敏、地塞米松和泼尼松龙这5种具有代表性的止痒药物,对药物的起效速度、止痒效果 和不良反应等进行比较研究。结果表明,用药4 h后,马来酸奥拉替尼的止痒作用最迅速和显 著,用药8 h、24 h、48 h和72 h后止痒效果最明显的为IL-31单克隆抗体。地塞米松和泼尼松龙 引起患犬白细胞和嗜中性粒细胞显著升高情况,其余药物处理未见异常。综上,说明马来酸 奥拉替尼和IL?31单克隆抗体在起效速度、止痒效果和安全性等方面具有明显优势。
关键词: 犬类, 瘙痒症, 止痒效果比较
CLC Number:
S857.5
SHI Guanwen, OU Zhaojia, LONG Haibin, RAO Gan, HE Jiaxin, HU Minhua. Effects of Different Antipruritic Drugs in Canine Pruritus[J]. Guangdong Journal of Animal and Veterinary Science, 2025, 50(2): 110-116.
石观稳, 欧兆佳, 何嘉欣, 龙海斌, 饶干, 胡敏华. 不同止痒药物对犬瘙痒症的疗效观察[J]. 广东畜牧兽医科技, 2025, 50(2): 110-116.
0 / Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.gdxmsykj.cn/EN/10.19978/j.cnki.xmsy.2025.02.17
http://www.gdxmsykj.cn/EN/Y2025/V50/I2/110